Tumour Trace first established collaborations with Oncquest Laboratories in New Delhi and NM Medical in Mumbai after Tumour Trace participated in the UKTI Healthcare Mission to India in February 2015.  The main aim of the subsequent clinical studies which were conducted 4-7th May 2015 at both clinical settings was to test three types of device and have face-to face discussions with pathologists over each cervical sample.

Oncquest is known for its excellence in Clinical Diagnostics. From its first avatar as an R&D focused entity, Oncquest has evolved into a reference laboratory in the field of Oncology, and more recently into a multi-platform Pathology Services provider with a core focus in Molecular Pathology and Surgical Pathology Services.

At Oncquest an Experiment was conducted in the Laboratory with Tumour Trace devices on 41 cervical cancer samples. There were two sample groups: one set of samples were carried out according to LBC technique (9 samples) and the second set according to standard PAP procedure (32 samples). Results were obtained from medical doctors using both the standard method and our method; we had a one-to-one evaluation of results with approximately 90% of results overlapping in accuracy. Comparisons were made on some of the samples: for stained, unstained fixed and unstained unfixed samples with the TT device and it was discovered that best results were from unstained unfixed samples.

NM Medical clinic in Mumbai was the pioneer of radiography, cardiology, pathology and preventative health check-ups in a diagnostic setting in India. In the 1980’s. NM Medical was the first to introduce Ultrasound into the private practice domain. NM Medical is ranked among the top 3 diagnostic facilities in Mumbai. 42 samples were prepared according to the standard PAP test procedure.Analysis of results was made following a one to one study with NM Hospital medical doctors, with more than 90% of results overlapping in accuracy.

Results obtained from this sample size showed a clear separation between healthy and unhealthy cervical samples. As the size sample was small with only two samples with histopathological confirmation of cervical cancer, we focused on a study that compared the efficacy of fresh, fixed and stained samples.

The TT team are currently back out in India this time over a three week period (30th Jan-20th Feb 2016) conducting a series of clinical trials – this time including testing the prototype device on oral samples as well as further studies with a larger volume of cervical samples. UKTI’s Nidhi Jain says of the burgeoning relationship “Tumour Trace has developed an amazing technology for cancer detection and being in India now, has been the most opportune time. As India steps up in its fight against cancer, the TT technology will be immensely useful in early, easy and accurate detection of cancers. UKTI has been happy to provide support to TT in India and we look forward to see TT playing this important role in our campaign of ‘making cancer history’. Congratulations to  Dr Koruga and his team!’ We will report back at the end of February results from this trip”.